What is the recommended dose of Relpax (eletriptan) for acute migraine attacks?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 13, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Relpax (Eletriptan) Dosing for Acute Migraine

The recommended dose of Relpax (eletriptan) is 40 mg as a single oral dose at the onset of migraine, with the option to repeat once after 2 hours if needed, not exceeding 80 mg total daily dose. 1

Standard Dosing Protocol

  • Initial dose: 20 mg or 40 mg taken at migraine onset 1
  • Maximum single dose: 40 mg 1
  • Repeat dosing: If headache persists or returns after 2 hours, a second dose may be taken at least 2 hours after the first dose 1
  • Maximum daily dose: 80 mg (total for the day) 1
  • Monthly limit: Safety of treating more than 3 migraine attacks per 30-day period has not been established 1

Dose Selection Rationale

The 40 mg dose is superior to 20 mg for most efficacy endpoints and should be the preferred starting dose for moderate to severe migraine. 1, 2 Clinical trials demonstrate that 40 mg eletriptan provides significantly better pain-free response at 2 hours (NNT 4.5) compared to 20 mg (NNT 9.9), while maintaining acceptable tolerability. 3

  • The 40 mg dose shows headache response rates of 54% at 2 hours and 28% pain-free rates 4
  • The 80 mg dose (not FDA-approved as maximum single dose in US) shows higher efficacy (68% response, 38% pain-free) but also increased adverse effects 4
  • Eletriptan 40 mg demonstrates superiority over naratriptan 2.5 mg and equivalence to almotriptan 12.5 mg, rizatriptan 10 mg, and zolmitriptan 2.5 mg 2, 5

Critical Timing Considerations

Administer eletriptan as early as possible during the migraine attack to maximize efficacy. 6, 7 The medication demonstrates superiority over placebo as early as 30 minutes after administration, with peak efficacy at 1-2 hours. 2, 5

Integration with Treatment Guidelines

  • First-line approach: Current guidelines recommend NSAIDs as initial therapy for mild-to-moderate migraine 6, 7
  • Triptan escalation: Eletriptan should be used when NSAIDs provide inadequate response or for moderate-to-severe attacks 6
  • Combination therapy: Consider combining triptans with fast-acting NSAIDs to prevent recurrence, as 40% of patients experience symptom return within 48 hours 6, 7

Important Contraindications and Precautions

Do not use eletriptan in patients with ischemic coronary artery disease, uncontrolled hypertension, or within 24 hours of other triptans or ergot-containing medications. 1

  • Contraindicated within 72 hours of potent CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir) 1
  • Contraindicated in patients with history of stroke, TIA, hemiplegic or basilar migraine, peripheral vascular disease, or ischemic bowel disease 1
  • Perform cardiovascular evaluation in triptan-naïve patients with multiple cardiovascular risk factors before prescribing 1

Medication Overuse Headache Prevention

Limit eletriptan use to no more than 2 days per week (or 10 days per month for triptans) to prevent medication overuse headache. 6, 7 Patients requiring more frequent acute treatment should be evaluated for preventive therapy. 6

Available Formulations

  • 20 mg tablets: Orange, round, film-coated, debossed 'EL 20' 1
  • 40 mg tablets: Orange, round, film-coated, debossed 'EL 40' 1

When Eletriptan Fails

If eletriptan provides inadequate response after adequate trial, consider: 6, 7

  • Trying a different triptan (failure of one does not predict failure of others) 7
  • Escalating to third-line agents (CGRP antagonists-gepants, ditans, or dihydroergotamine) 6
  • Initiating preventive therapy if attacks occur more than 2 days per month 6

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.